twenty-seven patients receiving a standard cytosine arabinoside and daunorubicin regimen as induction of reinduction therapy of acute myelogenous leukemia were randomly assigned to receive lithium carbonate , 300 mg t.i.d. , or no lithium .
C0011015
daunorubicin
C0023467
acute myelogenous leukemia